

Friday, July 8, 2022

Welcome Address

5:30 pm- 5:40 pm

Keynotes Lectures

Session Chair: **Kohei Miyazono**, The University of Tokyo, Tokyo, Japan

5:40 pm-7:00 pm

Pancreatic cancer is PRIMED to become an immunologic disease

Elizabeth M. Jaffee, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

Dissecting pancreatic cancer development with advanced mouse models

Yasuhiro Yamada, The University of Tokyo, Tokyo, Japan

Special Session: Patient and Public Involvement

7:00 pm- 7:30 pm

Pancreatic Cancer Research and PPI

Yoshiyuki Majima, Pancreatic Cancer Action Network, Tokyo, Japan

Welcome Party

7:50 pm- 9:50 pm

Saturday, July 9, 2022

Session 1: Stromal evolution and tumor microenvironment cross-talk and modeling

8:30 am-10:00 am

Dissecting T cell responses in human and mouse pancreatic cancer

Marina Pasca di Magliano, University of Michigan, Ann Arbor, Michigan

Understanding the biology of cancer-restraining fibroblasts in pancreatic cancer and its clinical application

Atushi Enomoto, Nagoya University Graduate School of Medicine, Nagoya, Japan

Contribution of tumor endothelial cells in tumor progression

Kyoko Hida, Hokkaido University, Hokkaido, Japan

Break

10:00 am- 10:20 am

Session 2: Inflammation

10:20 am-11:50 am

Microbial matters in pancreatic cancer: From inception to progression

Florencia McAllister, The University of Texas MD Anderson Cancer Center, Houston, Texas

The role of chromatin remodeling regulators in pancreatic cancer

Akihisa Fukuda, Kyoto University Graduate School of Medicine, Kyoto, Japan

Shift of immune-inflammatory microenvironment in regulating pancreatic cancer

Hideaki Ijichi, The University of Tokyo Hospital, Tokyo, Japan

Lunch and Poster View

11:50 am- 12:50 pm

Poster Presentation

12:50 pm- 2:20 pm

Session 3: Genetics, Kras, p53, and oncogenic signaling

2:20 pm-3:50 pm

Stress-adaptation in cancer: Role of stress granules in pancreatic tumorigenesis

Elda Grabocka, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

The importance of the p53 pathway in pancreatic neuroendocrine tumors

Rieko Ohki, National Cancer Center Research Institute, Tokyo, Japan

A whole-animal approach to identify therapeutic vulnerabilities in pancreatic cancer

Masahiro Sonoshita, Hokkaido University Institute for Genetic Medicine, Hokkaido, Japan

Break

3:50 pm- 4:10 pm

Session 4: Tumor heterogeneity, plasticity, and therapy resistance

4:10 pm-5:40 pm

Post-translational activation of MYC promotes cellular plasticity and aggressive, metastatic pancreatic cancer

Rosalie C. Sears, Oregon Health and Science University, Portland, Oregon

Title to be announced

Toshiro Sato, Keio University School of Medicine, Tokyo, Japan

Elucidation and control of cancer ecosystem using artificial cancer tissue

Keisuke Sekine, National Cancer Center Research Institute, Tokyo, Japan

Meet the Expert Evening

6:00 pm- 7:00 pm

Banquet

7:30 pm- 9:30 pm

Sunday, July 10, 2022

Session 5: Screening and early detection, liquid biopsy, biomarkers, and premalignant lesions

8:30 am-10:00 am

Early detection and cancer interception in pancreatic cancer

Anirban Maitra, The University of Texas MD Anderson Cancer Center, Houston, Texas

Increased levels of branched-chain amino acid associated with increased risk of pancreatic cancer in a prospective case-control study in a large cohort

Ryoko Katagiri, National Cancer Center Institute for Cancer Control, Tokyo, Japan

Premalignant lesions of the pancreatic cancer

Toru Furukawa, Tohoku University Graduate School of Medicine, Miyagi, Japan

Break

10:00 am- 10:20 am

Session 6: Clinical oncology and targeted therapies

10:20 am-11:50 am

Stronger together: Immuno-energizing non-IO drugs in novel combinations

Nilofer S. Azad, Johns Hopkins University, Baltimore, Maryland

Recent progress of precision medicine in the treatment of pancreatic cancer

Masashi Kanai, Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University

Current status and clinical trials in chemotherapy for pancreatic cancer in Japan

Junji Furuse, Kanagawa Cancer Center, Tokyo, Japan

Lunch

11:50 am- 12:50 pm

Session 7: Immunotherapy

12:50 pm- 2:20 pm

The role of altered lipid metabolism in pancreatic cancer cachexia

Stephanie K. Dougan, Dana-Farber Cancer Institute, Boston, Massachusetts

Inhibitor-induced stromal and metabolic reprogramming enhances pancreatic cancer therapy

Yasuyuki Kida, National Institute of Advanced Industrial Science and Technology, Ibaraki, Japan

Immune suppression in the tumor microenvironment

Hiroyoshi Nishikawa, Nagoya University Graduate School of Medicine, Nagoya, Japan; National Cancer Center, Tokyo, Japan

Break

2:20 pm-2:40 pm

Session 8: Metabolism, antioxidants, and cachexia

2:40 pm- 4:10 pm

The role of altered lipid metabolism in pancreatic cancer cachexia

Aaron Grossberg, Oregon Health & Science University, Portland, Oregon

The landscape of systemic metabolic alterations in cancer cachexia

Masahiro Aoki, Division of Pathophysiology, Aichi Cancer Center Research Institute

Translational research for clinical trials in human pancreatic cancer

Atsushi Ochiai, The Research Institute for Biological Sciences, Tokyo University of Sciences

Closing Remarks

4:10 pm- 4:20 pm